Sofinnova Ventures, a Menlo Park-based investment firm, has held the final close of its eight fund at $440m.
Sofinnova Venture Partners VIII will invest in later stage health care companies, with a specific focus on clinical stage drug development and spinouts.
At a geographic level, the fund will focus on both the United States and abroad, with a significant portion of the fund potentially invested in Europe.
Partners of SVP VIII include:
Jim Healy, MD, PhD,
Garheng Kong, MD, PhD,
Mike Powell, PhD,
Anand Mehra, MD,
Lars Ekman, MD, PhD, and
David Kabakoff, PhD.
Founded in 1974, Sofinnova Ventures also has offices in La Jolla, California.